Skip to main content

B7-1/CD80 Antibody (RM80) [DyLight 594]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-11976DL594

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-11976DL594

Key Product Details

Species Reactivity

Validated:

Mouse

Applications

Block/Neutralize, Flow Cytometry, Functional Assay, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot

Label

DyLight 594 (Excitation = 593 nm, Emission = 618 nm)

Antibody Source

Monoclonal Rabbit IgG Kappa Clone # RM80

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Summary for B7-1/CD80 Antibody (RM80) [DyLight 594]

Immunogen

This antibody was raised by immunising Sprague Dawley rats with a mouse B cell line, BCL1 and fusing immune splenocytes with P3U1 myeloma cells.

Specificity

This antibody is specific for murine B7-1/CD80, a ~55 kDa member of the Ig superfamily. B7-1/CD80 is expressed by macrophages, dendritic cells, activated B cells, and activated T cells. B7-1/CD80 has high affinity for binding to two T cell surface antigens, CD28 and CD152 (CTLA-4). The interaction of CD28 and CD152 with B7-1/CD80 is crucial in T-B cell communication leading to the activation of T and B cells, respectively.

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG Kappa

Applications for B7-1/CD80 Antibody (RM80) [DyLight 594]

Application
Recommended Usage

Block/Neutralize

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional Assay

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: B7-1/CD80

The B-lymphocyte activation antigen B7-1 (CD80) provides regulatory signals for T lymphocytes as a consequence of binding to the CD28 and CTLA4 ligands of T cells. After engagement of T-cell receptor with antigen in association with major histocompatibility complex class II, a second signal mediated through the binding of B7 to CD28 greatly upregulates the production of multiple lymphokines (1). The relatively small CTLA-4/B7-1 binding interface exhibits an unusually high degree of shape complementarity. CTLA-4 forms homodimers through a newly defined interface of highly conserved residues. This zipper-like oligomerization provides the structural basis for forming unusually stable signalling complexes at the T-cell surface, underscoring the importance of potent inhibitory signalling in human immune responses (2).

Alternate Names

B71, CD80

Gene Symbol

CD80

Additional B7-1/CD80 Products

Product Documents for B7-1/CD80 Antibody (RM80) [DyLight 594]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for B7-1/CD80 Antibody (RM80) [DyLight 594]



DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...